ReviewAntioxidants (Basel, Switzerland)2025
Calafate (
Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Maqui as a Chilean Functional Food: Antioxidant Bioactivity, Nutritional Value, and Health Applications.Antioxidants (Basel, Switzerland) · 2026Review
- Development of Cereal Bars Enriched with Andean Grains and Patagonian Calafate (Foods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Calafate berry, an ancient perennial shrub of South America (Chile and Argentina), produces a high antioxidant capacity berry with a high polyphenol (1344.2-6553 mg GAE/100 g d.w.) and anthocyanin (26.5-80 mg C-3-G/100 g d.w.) content. The beneficial effects of calafate berries on human health are related to the anti-inflammatory, hypoglycemic, anticancer, and antioxidant properties that the berries possess, which have been confirmed through evidence to date, primarily from in vitro, ex vivo, and animal studies. Several investigations have shown a relationship between the consumption of calafate and a reduction in the risk of contracting cardiovascular diseases (CVD). This was evident in changes in plasma level biomarkers related to CVD, such as thrombomodulin (-24%), adiponectin (+68%), sE-selectin (-34%), sICAM-1 (-24%) and proMMP-9 (-31%), and changes in the production of OH radicals in plasma (-17%) after calafate intake. Calafate may have an antithrombotic role that supports cardiovascular health by lowering the Atherogenic and Cardiovascular Risk Indices. Various authors indicate delphinidin-3-glucoside (384-386 mg/100 g) as the primary bioactive compound responsible for the beneficial properties of Calafate. Although some studies report calafate's health benefits, scientific evidence, especially in humans, remains limited. Meanwhile, Chile is working to domesticate and cultivate calafate, aiming to turn it from a wild native berry into a sustainable crop for use in the antioxidants and nutraceuticals industry. The lack of human clinical trials emphasizes the need for future research to validate calafate's health benefits berry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.